Revelation Biosciences, Inc. (REVB)

Market Cap	2.21M -65.4%
Revenue (ttm)	n/a
Net Income	-17.84M
EPS	-39.98
Shares Out	569.06K
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,473
Open	3.660
Previous Close	3.560
Day's Range	3.560 - 3.940
52-Week Range	3.080 - 40.600
Beta	-0.10
Analysts	n/a
Price Target	124.25 (+3,094.09%)
Earnings Date	Nov 5, 2026

About REVB

Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response. It also engages in the prevention and treatment of disease by developing and commercializing therapeutics that modulate the...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2020
• Employees: 9
• Stock Exchange: Nasdaq
• Ticker Symbol: REVB
• Website: https://www.revbiosciences.com

Analyst Summary

The average 12-month stock price target for REVB is $124.25, which is an increase of 3,094.09% from the latest price.

Price Target

$124.25

(3,094.09% upside)

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Nov 7, 2026

Data Sources Report a data error